PAVO is an open-label Phase II study investigating if the study drug, a PARP inhibitor called niraparib (Zejula), is safe and effective for certain people who have been diagnosed with an
advanced solid tumor with either an inherited or tumor PALB2 mutation.

This study is looking at how well a drug called ART4215 works either alone or when combined with the PARP inhibitor talazoparib in people with different types of advanced cancers. ART4215 is an oral targeted therapy that is designed to keep cancer cells from repairing DNA damage. 

This study is for people with advanced or metastatic endometrial cancer that has progressed on or after platinum-based chemotherapy. Participants will receive retifanlimab (a type of immunotherapy) alone or in combination with other immunotherapies or targeted therapies.

This study for people with Stage III or Stage IV endometrial cancer will look at how well the combination of an immunotherapy plus targeted therapy and chemotherapy works compared with chemotherapy alone. 

This study will look at safety and affectiveness of the targeted therapy CYH33 combined with the PARP inhibitor olaparib in people with advanced cancers and a DNA damage repair (DDR) gene mutation whose cancer got worse on, or after receiving a PARP inhibitor. The study will also enroll people with recurrent, platinum resistant ovarian cancer. In addition to safety and efficacy, the study will test whether the combination of CYH33 and olaparib can block tumor growth and overcome a patient’s resistance to PARP inhibitor treatment.

The purpose of this study is to evaluate the safety, effectiveness, and tolerability of using the immunotherapy drugs nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors resistant to prior PD-L1 therapy.

Both Nivolumab and Relatlimab are a type of immunotherapy known as immune checkpoint inhibitors. Immune checkpoint inhibitors are drugs that prevent cancer cells from switching off immune cells. This allows the immune system to find, unmask and destroy cancer cells.

This study will look at how well the targeted therapy TAS-117 works for treating people with an inherited PTEN mutation and advanced or metastatic solid tumors (excluding primary brain tumors).

The purpose of this study is to determine whether the addition of the immunotherapy agent pembrolizumab to radiation therapy is more effective than radiation therapy alone in reducing the risk of cancer recurrence in patients with newly diagnosed stage I-II endometrial cancer that is MSI-High.

The purpose of this study is to test the effectiveness, safety, and tolerability of Nivolumab on patients with metastatic or recurrent uterine cancer. 

Nivolumab is a type of immunotherapy known as an immune checkpoint inhibitor. Immune checkpoint inhibitors are drugs that prevent cancer cells from switching off immune cells. This allows the immune system to find, unmask and destroy cancer cells.

The LODESTAR study is evaluating the response of the PARP inhibitor rucaparib in people with advanced solid tumors (including breast, ovarian, pancreatic, prostate and other cancers) who have an inherited mutation or an acquired mutation in any of the following genes: BRCA1, BRCA2, PALB2, RAD51C, RAD51D, BARD1, BRIP1, FANCA, NBN, RAD51 or RAD51B.